Nanobiotix S.A. (NBTX)
Health Care
NBTX is listed on Nasdaq, where its shares have traded since December 11, 2020. It represents shares of Nanobiotix S.A., which reports its financial results in EUR. SentiSense covers it in the Health Care sector.
About Nanobiotix S.A.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.
Latest reported results
Nanobiotix S.A. reported revenue of 5.6 million EUR for Q2 FY2026, down 79.2% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 19 institutions reported holding NBTX, with 5.8 million shares worth $218.4 million in aggregate. The largest reported holders were Johnson & Johnson, Morgan Stanley and Jane Street Group. Of the 5 largest reported holders, 3 opened new positions in NBTX, 1 added shares and 1 held its position unchanged during the quarter.
More on NBTX
- NBTX sentiment: whether news and social coverage of Nanobiotix S.A. leans bullish or bearish, and the stories driving it.
- NBTX ownership: all 19 reporting institutions, plus insider and congressional trades.
- NBTX financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
Frequently asked questions
What does Nanobiotix S.A. do?
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients.
What sector is NBTX in?
SentiSense classifies Nanobiotix S.A. in the Health Care sector.
Where does NBTX stock trade?
NBTX is listed on Nasdaq, where its shares have traded since December 11, 2020. It represents shares of Nanobiotix S.A., which reports its financial results in EUR.
Who is the CEO of Nanobiotix S.A.?
Laurent Levy is the chief executive officer of Nanobiotix S.A..